keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimers disease treatment

keyword
https://www.readbyqxmd.com/read/28231543/date-seed-extract-ameliorates-%C3%AE-amyloid-induced-impairments-in-hippocampus-of-male-rats
#1
Farzaneh Dehghanian, Taj Pari Kalantaripour, Khadijeh Esmaeilpour, Leila Elyasi, Hakime Oloumi, Fatmeh Mehdi Pour, Majid Asadi-Shekaari
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder among the elderly. Because the existing treatments for Alzheimer's disease only offer limited symptomatic alleviation, more efficient therapeutic agents are urgently needed. Date seed is a hepatoprotective and neuroprotective agent. Date seed extract (DSE) has bioactive components like phenolics, flavonoids, and vitamins. In view of the ameliorative effects of DSE against an oxidative injury, the current study was designed to reveal whether DSE has a neuroprotective resource in the rat model of Alzheimer's disease...
February 20, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28231531/concentrations-of-antibodies-against-%C3%AE-amyloid-40-42-monomer-and-oligomers-in-chinese-intravenous-immunoglobulins
#2
Shengliang Ye, Renyong Zeng, Peng Jiang, Mingxia Hou, Fengjuan Liu, Zongkui Wang, Xi Du, Jing Yuan, Yunhua Chen, Haijun Cao, Li Ma, Changqing Li
Intravenous immunoglobulin (IVIg) preparations are being investigated as a potential agent for treatment or prevention of Alzheimer's disease (AD). Antibodies towards soluble β-amyloid (Aβ) contained in IVIg were considered to be the major component contributing to the beneficial effect of the preparations in pilot studies. This study compared the antibody concentrations against Aβ in Octagam(®) IVIg (Octapharma) and 9 IVIg preparations from different Chinese manufacturers by ELISA, using Aβ40 monomer, Aβ40 soluble oligomers, Aβ42 monomer and Aβ42 soluble oligomers as the antigens...
February 17, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28230352/disease-modifying-effects-of-m1-muscarinic-acetylcholine-receptor-activation-in-an-alzheimer-s-disease-mouse-model
#3
Evan P Lebois, Jason P Schroeder, Thomas J Esparza, Thomas M Bridges, Craig W Lindsley, P Jeffrey Conn, David L Brody, John Scott Daniels, Allan I Levey
Alzheimer's Disease (AD) is the leading cause of dementia worldwide and currently no disease-modifying therapy is available to slow or prevent AD, underscoring the urgent need for neuroprotective therapies. Selective M1 muscarinic acetylcholine receptor (mAChR) activation is an attractive mechanism for AD therapy since M1 mediates key effects on memory, cognition, and behavior and has potential for disease-modifying effects on Aβ formation and tau phosphorylation. To validate M1 as a neuroprotective treatment target for AD, the M1-selective agonist, VU0364572, was chronically dosed to 5XFAD mice from a young age preceding Aβ pathology (2 months) to an age where these mice are known to display memory impairments (6 months)...
February 23, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28229638/intranasal-insulin-treatment-improves-memory-and-learning-in-a-rat-amyloid-beta-model-of-alzheimer-s-disease
#4
S Farzampour, A Majdi, S Sadigh-Eteghad
Recently, insulin has been used as a pro-cognitive agent for the potential treatment of Alzheimer's disease (AD), because of its ability to cross the brain-blood barrier (BBB) by a saturable transport system. This study has been designed to evaluate the effects of intranasal insulin regimen, as a bypass system of BBB, on spatial memory in amyloid-beta (Aβ) model of AD in rat. Unilateral infusion of Aβ25-35 (10 nmol/2 µl/rat) into the lateral ventricular region of brain was used to produce a rat model of AD...
September 2016: Physiol Int
https://www.readbyqxmd.com/read/28229126/assessing-quality-of-life-in-alzheimer-s-disease-implications-for-clinical%C3%A2-trials
#5
Kristin Kahle-Wrobleski, Wenyu Ye, David Henley, Ann Marie Hake, Eric Siemers, Yun-Fei Chen, Hong Liu-Seifert
INTRODUCTION: Characterization of the quality of life (QOL) in Alzheimer's disease (AD) scale within the context of a clinical trial may inform its applicability in future trials. METHODS: Using data from 1322 patients enrolled in two phase-III studies (EXPEDITION 1 [NCT00905372] and 2 [NCT00904683]) of intravenous solanezumab in outpatients with mild AD dementia, correlations between patient- and caregiver-assessed QOL and between QOL and clinical outcome measures were examined...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28228653/drug-prescription-appropriateness-in-the-elderly-an-italian-study
#6
Nicola Allegri, Federica Rossi, Federica Del Signore, Paolo Bertazzoni, Roberto Bellazzi, Giorgio Sandrini, Tomaso Vecchi, Davide Liccione, Alessia Pascale, Stefano Govoni
PURPOSE: Correct drug prescription in the elderly is a difficult task that requires careful survey of the current pharmacological therapies. In this article, we reviewed the drug prescriptions provided to 860 persons aged 65 years or over, residing in a small city of Lombardy, Italy. METHODS: Subjects were recruited from a local nursing home, the Pavia and Vigevano Neuropsychological Center for Alzheimer's Disease, general practitioners' offices, and the local University of the Third Age...
2017: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/28227862/effects-of-high-frequency-rtms-on-sleep-deprivation-a-pilot-study
#7
D P Martinez-Cancino, J Azpiroz-Leehan, L Jimenez-Angeles, A Garcia-Quintanar, R Santana-Miranda, D P Martinez-Cancino, J Azpiroz-Leehan, L Jimenez-Angeles, A Garcia-Quintanar, R Santana-Miranda, A Garcia-Quintanar, L Jimenez-Angeles, R Santana-Miranda, J Azpiroz-Leehan, D P Martinez-Cancino
Transcranial magnetic stimulation is a neurostimulation technique which has the potential to serve as a unique research tool for investigating a wide variety of fields in cognitive neuroscience. TMS has been approved by the FDA to serve as a treatment to depression and has also been used to evaluate its effects among several conditions such as Alzheimer, Parkinson disease, chronic pain and stroke. High frequency TMS has been previously used with the intention to measure and modulate the negative effects of sleep deprivation in cognitive performance, but there is no consensus about the ideal protocol yet...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28227007/identification-of-blood-biomarkers-for-use-in-point-of-care-diagnosis-tool-for-alzheimer-s-disease
#8
E Jammeh, P Zhao, C Carroll, S Pearson, E Ifeachor, E Jammeh, P Zhao, C Carroll, S Pearson, E Ifeachor, C Carroll, E Jammeh, E Ifeachor, S Pearson, P Zhao
Early diagnosis of Alzheimer's Disease (AD) is widely regarded as necessary to allow treatment to be started before irreversible damage to the brain occur and for patients to benefit from new therapies as they become available. Low-cost point-of-care (PoC) diagnostic tools that can be used to routinely diagnose AD in its early stage would facilitate this, but such tools require reliable and accurate biomarkers. However, traditional biomarkers for AD use invasive cerebrospinal fluid (CSF) analysis and/or expensive neuroimaging techniques together with neuropsychological assessments...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28226665/changes-in-the-eeg-amplitude-as-a-biomarker-for-early-detection-of-alzheimer-s-disease
#9
Ali H Al-Nuaimi, Emmanuel Jammeh, Lingfen Sun, Emmanuel Ifeachor, Ali H Al-Nuaimi, Emmanuel Jammeh, Lingfen Sun, Emmanuel Ifeachor, Emmanuel Jammeh, Lingfen Sun, Ali H Al-Nuaimi, Emmanuel Ifeachor
The rapid increase in the number of older people with Alzheimer's disease (AD) and other forms of dementia represents one of the major challenges to the health and social care systems. Early detection of AD makes it possible for patients to access appropriate services and to benefit from new treatments and therapies, as and when they become available. The onset of AD starts many years before the clinical symptoms become clear. A biomarker that can measure the brain changes in this period would be useful for early diagnosis of AD...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28223223/berberine-improves-cognitive-impairment-by-promoting-autophagic-clearance-and-inhibiting-production-of-%C3%AE-amyloid-in-app-tau-ps1-mouse-model-of-alzheimer-s-disease
#10
Min Huang, Xin Jiang, Yubin Liang, Qiong Liu, Siyan Chen, Yi Guo
This study investigates the neuroprotective properties of berberine (a natural isoquinoline alkaloid isolated from the Rhizoma coptidis) and finds that berberine could promote β-amyloid (Aβ) clearance and inhibit Aβ production in the triple-transgenic mouse model of Alzheimer's disease (3×Tg-AD). During the study, berberine was first administrated to treat 3×Tg-AD mice and primary neurons. Morris water maze assay, western blotting, enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining and histological analysis, transmission electron microscopic analysis were then used to evaluate the effects of the berberine administration...
February 20, 2017: Experimental Gerontology
https://www.readbyqxmd.com/read/28223210/a-novel-glp-1-gip-dual-receptor-agonist-protects-from-6-ohda-lesion-in-a-rat-model-of-parkinson-s-disease
#11
Jaishree Jalewa, Mohit Kumar Sharma, Simon Gengler, Christian Hölscher
The incretins glucagon-like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are growth factors that have shown neuroprotective effects in animal models of Parkinson's and Alzheimer's disease. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in a clinical trial in Parkinson's disease (PD) patients. GLP-1 analogues are currently on the market as treatments for type II diabetes. We previously showed that the novel dual agonist (DA-JC1) was effective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD...
February 20, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28223162/the-roles-of-histamine-and-its-receptor-ligands-in-central-nervous-system-disorders-an-update
#12
REVIEW
Weiwei Hu, Zhong Chen
The neurotransmitter histamine receives less attention compared with other biogenic amines, because of its moderate action in the central nervous system (CNS). However, recent evidence suggests that histamine plays an important role in multiple CNS disorders including insomnia, narcolepsy, Parkinson's diseases, schizophrenia, Alzheimer's disease, and cerebral ischemia. New insights are emerging into the potential roles of histamine receptors as targets for the treatment of these diseases. Although some histamine related agents have failed in clinical trials, current preclinical studies suggest that this neurotransmitter may still have extensive applications in treating CNS disorders, however, advanced studies are warranted...
February 18, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28222815/cognitive-stimulation-therapy-as-a-sustainable-intervention-for-dementia-in-sub-saharan-africa-feasibility-and-clinical-efficacy-using-a-stepped-wedge-design
#13
Stella-Maria Paddick, Sarah Mkenda, Godfrey Mbowe, Aloyce Kisoli, William K Gray, Catherine L Dotchin, Laura Ternent, Adesola Ogunniyi, John Kissima, Olaide Olakehinde, Declare Mushi, Richard W Walker
BACKGROUND: Cognitive stimulation therapy (CST) is a psychosocial group-based intervention for dementia shown to improve cognition and quality of life with a similar efficacy to cholinesterase inhibitors. Since CST can be delivered by non-specialist healthcare workers, it has potential for use in low-resource environments, such as sub-Saharan Africa (SSA). We aimed to assess the feasibility and clinical effectiveness of CST in rural Tanzania using a stepped-wedge design. METHODS: Participants and their carers were recruited through a community dementia screening program...
February 22, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/28222532/prevalence-of-use-of-cardiovascular-drugs-in-dementia-patients-treated-in-general-practices-in-germany
#14
Louis Jacob, Jens Bohlken, Karel Kostev
BACKGROUND: Dementia is a chronic disease associated with numerous cardiovascular disorders. OBJECTIVE: To analyze the prevalence of cardiovascular drug use in dementia patients treated in general practices in Germany. METHODS: The present study included patients who were diagnosed with dementia (Alzheimer's disease, vascular dementia, or unspecified dementia) in 2015. The main outcome measure was the proportion of patients using cardiovascular drugs...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28222530/generation-and-partial-characterization-of-rabbit-monoclonal-antibody-to-amyloid-%C3%AE-peptide-1-37-a%C3%AE-37
#15
Pankaj D Mehta, Jean-Francois Blain, Emily A Freeman, Bruce A Patrick, Marc Barshatzky, Lori A Hrdlicka, Sangita P Mehta, Janusz Frackowiak, Bozena Mazur-Kolecka, Jerzy Wegiel, Holger Patzke, David L Miller
Secreted soluble amyloid-β 1-37 (Aβ37) peptide is one of the prominent Aβ forms next to Aβ40, and is found in cerebrospinal fluid (CSF) and blood. Recent studies have shown the importance of quantitation of CSF Aβ37 levels in combination with Aβ38, Aβ40, and Aβ42 to support the diagnosis of patients with probable Alzheimer's disease (AD), and the value of antibody to Aβ37 to facilitate drug discovery studies. However, the availability of reliable and specific monoclonal antibody to Aβ37 is very limited...
February 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28222521/the-effects-of-lw-afc-on-the-hippocampus-transcriptome-in-senescence-accelerated-mouse-prone-8-strain-a-mouse-model-of-alzheimer-s-disease
#16
Jianhui Wang, Yang Liu, Xiaorui Cheng, Xiaorui Zhang, Feng Liu, Gang Liu, Shanyi Qiao, Ming Ni, Wenxia Zhou, Yongxiang Zhang, Fei Li
The senescence-accelerated mouse prone 8 (SAMP8) strain is considered a robust experimental model for developing preventative and therapeutic treatments for Alzheimer's disease (AD), a neurodegenerative disease which cannot be effectively prevented, halted, or cured. Our previous studies showed that LW-AFC, a new formula derived from the classical traditional Chinese medicinal prescription Liuwei Dihuang decoction, ameliorates cognitive deterioration in PrP-hAβPPswe/PS1ΔE9 transgenic mice and SAMP8 mice. This study aims to investigate the mechanism that mediates how LW-AFC improves cognitive deficit on the basis of the transcriptome...
February 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28222509/galantamine-response-associates-with-agitation-and-the-prefrontal-cortex-in-patients-with-alzheimer-s-disease
#17
Sachiko Nakayama, Akimitsu Suda, Hajime Nakanishi, Yumiko Motoi, Nobutaka Hattori
Behavioral and psychological symptoms of dementia (BPSD) occur in up to 80% of AD patients and represent one of the largest factors contributing to caregiver burden. To analyze the effect of galantamine on BPSD and caregiver burden, we treated a total of 50 patients with mild AD for 12 weeks and evaluated them using the Neuropsychiatric Inventory (NPI) and Japanese version of the Zarit Caregiver Burden Interview (ZBI). We also performed regional cerebral blood flow single photon emission computed tomography (rCBF SPECT) at baseline using three-dimensional sterotatic surface projections...
February 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28222508/chronic-lithium-treatment-in-a-rat-model-of-basal-forebrain-cholinergic-depletion-effects-on-memory-impairment-and-neurodegeneration
#18
Francesca Gelfo, Debora Cutuli, Annalisa Nobili, Paola De Bartolo, Marcello D'Amelio, Laura Petrosini, Carlo Caltagirone
Alzheimer's disease (AD) is an age-related neurodegenerative disorder with multifactorial etiopathogenesis, characterized by progressive loss of memory and other cognitive functions. A fundamental neuropathological feature of AD is the early and severe brain cholinergic neurodegeneration. Lithium is a monovalent cation classically utilized in the treatment of mood disorders, but recent evidence also advances a beneficial potentiality of this compound in neurodegeneration. Interestingly, lithium acts on several processes whose alterations characterize the brain cholinergic impairment at short and long term...
February 7, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28222507/recent-progress-in-alzheimer-s-disease-research-part-1-pathology
#19
Francis T Hane, Brenda Y Lee, Zoya Leonenko
The field of Alzheimer's disease (AD) research has grown exponentially over the past few decades, especially since the isolation and identification of amyloid-β from postmortem examination of the brains of AD patients. Recently, the Journal of Alzheimer's Disease (JAD) put forth approximately 300 research reports which were deemed to be the most influential research reports in the field of AD since 2010. JAD readers were asked to vote on these most influential reports. In this 3-part review, we review the results of the 300 most influential AD research reports to provide JAD readers with a readily accessible, yet comprehensive review of the state of contemporary research...
February 10, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28222505/cognitive-training-interventions-for%C3%A2-patients-with-alzheimer-s-disease-a%C3%A2-systematic-review
#20
Eeva-Liisa Kallio, Hanna Öhman, Hannu Kautiainen, Marja Hietanen, Kaisu Pitkälä
BACKGROUND: Cognitive training (CT) refers to guided cognitive exercises designed to improve specific cognitive functions, as well as enhance performance in untrained cognitive tasks. Positive effects of CT on cognitive functions in healthy elderly people and persons with mild cognitive impairment have been reported, but data regarding the effects of CT in patients with dementia is unclear. OBJECTIVE: We systematically reviewed the current evidence from randomized controlled trials (RCTs) to find out if CT improves or stabilizes cognition and/or everyday functioning in patients with mild and moderate Alzheimer's disease...
2017: Journal of Alzheimer's Disease: JAD
keyword
keyword
89837
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"